Open AccessDramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient
Author(s) -
Saito Shunichi,
Toyokawa Gouji,
Momosaki Seiya,
Kozuma Yuka,
Shoji Fumihiro,
Yamazaki Koji,
Takeo Sadanori
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14051
Subject(s) - medicine , pembrolizumab , carboplatin , chemotherapy , lung cancer , carcinoma , pathological , regimen , oncology , radiation therapy , lung , small cell carcinoma , radiology , cancer , surgery , immunotherapy , cisplatin
Immune checkpoint inhibitors with chemotherapy have been shown to exhibit remarkable efficacy for advanced non‐small‐cell lung carcinoma and are under investigation as an induction therapy. However, the significance of preoperative therapy with pembrolizumab + chemotherapy for surgically resectable non‐small‐cell lung carcinoma still remains unclear. Here, we report a case of stage IIIB non‐small‐cell lung carcinoma that underwent salvage surgery after three cycles of pembrolizumab + carboplatin + nab‐paclitaxel. Computed tomography revealed the remarkable decrease in tumor volume by 81%. A pathological examination showed that viable neoplastic cells were observed in <1% of the total tumorous lesion suggesting near pathological complete response. This case suggests that this regimen might be a good option as induction therapy for non‐small‐cell lung carcinoma.